A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 6, 2001, Pages 541-544

  Zhou, Shufeng ^a   Kestell, Philip ^b   Tingle, Malcolm D ^a   Ching, Lai Ming ^b   Paxton, James W ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cyproheptadine; Diclofenac; DMXAA; Drug interaction; Thalidomide

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; CYPROHEPTADINE; DICLOFENAC; SN 24350; THALIDOMIDE;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; DRUG PROTEIN BINDING; LIVER MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CYPROHEPTADINE; DICLOFENAC; DRUG INTERACTIONS; GLUCURONIDES; HYDROXYLATION; MALE; MICE; MICROSOMES, LIVER; RATS; RATS, WISTAR; THALIDOMIDE; XANTHENES; XANTHONES;

EID: 0035001126     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100285     Document Type: Article

References (31)

1. 1. Bauer KS, Dixon SC, Figg WD (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation which is species-dependent. Biochem Pharmacol 55:1827-1834
2. 2. Bort R, Mace K, Boobis A, Gomez-Lechon MJ, Pfeifer A, Castell J (1999) Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 58:787-796
3. 3. Braun AG, Harding FA, Weinreb SL (1986) Teratogen metabolism: thalidomide activation is mediated by cytochrome P450. Toxicol Appl Pharmacol 82:175-179
4. 4. Burchell B, Brieley CH, Rance D (1995) Specificity of human UDP-glucuronosyl-transferases and xenobiotic glucuronidation. Life Sci 57:1818-1831
5. 5. Butler H (1977) Effect of thalidomide on a promsimian: greater galago (Galago crassicaudatus). J Med Primatol 6:319-324
6. 6. Casini G, Ferappi M (1964) Preparation of one optical antipode of 2-phthalimidoglutarimide. Farmaco 19:563-565
7. 7. Ching L-M, Browne WL, Tchernegovski R, Gregory T, Baguley BC, Palmer BD (1998) Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity. Br J Cancer 78:336-343
8. 8. Fabro S, Smith RL (1966) Teratogenic activity of thalidomide in the rabbit. J Pathol Bacteriol 91:511-519
9. 9. Figg WD, Reed E, Green S, Pluda JM (1999) Thalidomide: a prodrug that inhibits angiogenesis. In: Teicher BA (ed) Antiangiogenic agents in cancer therapy. Humana Press, Totowa, pp 407-422
10. 10. Green MD, Bishop WP, Tephly TR (1995) Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab Dispos 23:299-302
11. 11. Green MD, King CD, Mojarrabi B, Mackenzie PI, Tephly TR (1998) Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos 26:507-512
12. 12. Kestell P, Paxton JW, Rewcastle GW, Dunlop I, Baguley BC (1999) Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit. Cancer Chemother Pharmacol 43:323-330
13. 13. Kestell P, Zhao L, Ching L-M, Baguley BC, Paxton JW (2000) Modulation of the plasma pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid by thalidomide in mice. Cancer Chemother Pharmacol 46:135-141
14. 14. Klausner JD, Freedman VH, Kaplan G (1996) Thalidomide as an anti-TNF-alpha inhibitor - implications for clinical use. Clin Immunol Immunopathol 81:219-223
15. 15. Landi MT, Sinha R, Lang NP, Kadlubar FF (1999) In: Ryder W (ed) Metabolic polymorphisms and susceptibility to cancer. IARC Scientific Publications, Lyon, pp 173-195
16. 16. Miners JO, Valente L, Lillywhite KJ, Mackenzie PI, Burchell B, Baguley BC, Kestell P (1997) Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Res 57:284-289
17. 17. Monshouwer M, Witkamp RF, Numeijer SM, van Amsterdam JG, van Miert ASJPAM (1996) Suppression of cytochrome P450-and UDP glucuronosyltransferase-dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes. Toxicol Appl Pharmacol 137:237-244
18. 18. Reist M, Carrupt PA, Francotte E, Testa B (1998) Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem Res Toxicol 11:1521-1528
19. 19. Rewcastle GW, Atwell GJ, Baguley BC, Calveley SB, Denny WA (1989) Potential antitumour agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumour in vivo. J Med Chem 32:793-799
20. 20. Robson RA, Matthews AP, Miners JO, McManus ME, Meyer UA, Hall PD, Birkett DJ (1987) Characterisation of theophylline metabolism by human liver microsomes. Br J Clin Pharmacol 24:293-300
21. 21. Schumacher H, Smith RL, Williams RT (1965) The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br J Pharmacol 25:324-337
22. 22. Schumacher H, Blake DA, Gillette JR (1968) Disposition of thalidomide in rabbits and rats. J Pharmacol Exp Ther 160:201-211
23. 23. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Garter FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85
24. 24. Takemura S, Minamiyama Y, Imaoka S, Funae Y, Hirohashi K, Inoue M, Kinoshita H (1999) Hepatic cytochrome P450 is directly inactivated by nitric oxide, not by inflammatory cytokines, in the early phase of endotoxemia. J Hepatol 30:1035-1044
25. 25. Teo SK, Sabourin PJ, O'Brien K, Kook KA, Thomas SD (2000) Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J Biochem Mol Toxicol 14:140-147
26. 26. Zhao L, Ketsell P, Zhuang L, Baguley BC (2001) Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetic of 5,6-dimethylxanthenone-4-acetic (DMXAA). Cancer Chemother Pharmacol (in press)
27. 27. Zhou SF, Paxton JW, Tingle MD, McCall J, Kestell P (1999) Determination of two major metabolites of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection. J Chromatogr B 734:129-136
28. 28. Zhou SF, Paxton JW, Tingle MD, Kestell P (2000) Identification of the human liver cytochrome P450 isozyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metab Dispos 28:1449-1456
29. 29. Zhou SF, Paxton JW, Tingle MD, Kestell P, Ching L-M (2001) In vitro and in vivo kinetic interactions of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac. Cancer Chemother Pharmacol (in press)
30. 30. Zhou SF, Paxton JW, Kestell P, Tingle MD (2001) Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and blood cells in various species. J Pharm Pharmacol (in press)
31. 31. Zhou SF, Paxton JW, Tingle MD, Kestell P, Jameson MB, Thomson PI, Baguley BC (2001) Identification and reactivity of the major metabolite (b-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans. Xenobiotica (in press)